T-cell Lymphoma Market to Surpass US$ 2,495.4 Million by 2028

Global T-cell Lymphoma Market, by Lymphoma Type (Peripheral T-cell Lymphoma (Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angio-immuno-blastic T-cell Lymphoma, Others (Intestinal T-cell Lymphoma, Follicular T-cell lymphoma, etc.)), and T-cell Lymphoblastic Lymphoma), by Therapy (Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, and Others (Antiviral Therapy, etc.)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 1,627.1 million in 2021 and is expected to exhibit a CAGR of 9.8% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.

Key players operating in the market are focusing on launches and regulatory approvals of new drugs for treatment of T-cell lymphoma and this is expected to drive the market growth over the forecast period.

For instance, in August 2018, Kyowa Kirin Co., Ltd., a Japan based pharmaceutical company, received the U.S. Food and Drug Administration approval for its humanized monoclonal antibody Poteligeo (Mogamulizumab-kpkc) to be used in the treatment of T-cell leukemia, cutaneous T-cell lymphomas, and T-cell lymphomas in adult patients.

Global T-cell Lymphoma Market – Impact of Coronavirus (Covid-19) Pandemic

COVID-19 outbreak was first reported on December 31, 2019, in Wuhan, China. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 256 million cases and 5.1 million deaths due to Coronavirus (COVID-19) were reported up till November 21, 2021, across the globe.

The COVID-19 pandemic has negatively affected several markets across the globe and is also expected to hamper the demand and supply in global T-cell lymphoma market, owing to lockdowns, halt of clinical trials related to cancer and lack of labour involved in manufacturing of drugs. For instance, according to an article published by the Nepal Journal of Epidemiology in September 2020, COVID-19 pandemic has raised various challenges in the field of clinical research such as implementation of strict guidelines which restrict physical interaction between the participants of a clinical trial study and the clinical trial personnel, thus leading to halt of clinical trials during the COVID-19 pandemic.

Browse 41 Market Data Tables and 30 Figures spread through 168 Pages and in-depth TOC on “T-cell Lymphoma Market”- Global Forecast to 2028, by Lymphoma Type (Peripheral T-cell Lymphoma (Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angio-immuno-blastic T-cell Lymphoma, Others (Intestinal T-cell Lymphoma, Follicular T-cell lymphoma, etc.)), and T-cell Lymphoblastic Lymphoma), by Therapy (Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, and Others (Antiviral Therapy, etc.)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),

To know the latest trends and insights prevalent in the global T-cell lymphoma market, click the link below:

https://www.coherentmarketinsights.com/market-insight/t-cell-lymphoma-market-4799

Key players operating in the market are focusing on adoption of inorganic growth strategies such as collaborations, acquisitions, and others in order to strengthen their position in the global T-cell lymphoma market. For instance, in June 2021, Orion Corporation, a Finland based pharmaceutical company, entered into a collaboration with Finnish Red Cross Blood Service, a Finland based provider of blood service, to develop new CAR (Chimeric antigen receptor) T-cell cancer therapy. CAR T-cell therapy can be used to treat patients with refractory or relapsed T-cell lymphoma, thus such collaborations are expected to fuel the growth of global T-cell lymphoma market.

Key Takeaways of the Global T-cell Lymphoma Market:

• The global T-cell lymphoma market is expected to exhibit a CAGR of 9.8% over the forecast period, owing to growing regulatory approvals of new T-cell lymphoma therapies. For instance, in November 2018, Seagen Inc., a U.S. based biotechnology company, received the U.S. FDA approval for its anticancer agent brentuximab vedotin (BV) for the treatment of previously untreated systemic anaplastic large cell lymphoma (a type of T-cell lymphoma) in adult patients.
• Among therapy, chemotherapy is expected to account for largest market share in 2021, owing to recent chemotherapy drug launches for the treatment of one or more types of T-cell lymphomas. For instance, in May 2021, Eisai Co., Ltd., a Japan based pharmaceutical company, announced the launch of its anticancer drug Remitoro (Intravenous Drip Infusion) in Japan for treatment of relapsed or refractory Cutaneous T-cell Lymphoma (CTCL) and Peripheral T-cell Lymphoma (PTCL).
• Key players operating in the global T-cell lymphoma market include F. Hoffmann-La Roche Ltd, Biocryst Pharmaceuticals Inc., Bristol-Myers Squibb Company, Kyowa Kirin Co., Ltd., Genmab A/S, Seagen Inc., GlaxoSmithKline plc., Johnson and Johnson Private Limited, Elorac, Acrotech Biopharma, Merck and Co. Inc., Novartis AG, SHIONOGI & Co., Ltd., Spectrum Pharmaceuticals Inc., and Bausch Health Companies Inc.